Title: Synergism between Fluconazole and Terminalia catappa Extract and its Use in the Treatment of Candida-infected Tenebrio molitor Larvae / Título: Sinergismo entre Fluconazol e o Extrato de Terminalia catappa e seu uso no tratamento de larvas de Tenebrio molitor infectadas com Candida

Aline Michelle Silva Mendonça, Carlos Henrique Lopes Rocha, Carmem Duarte Lima Campos, Alan Kardec Duailibe Barros Filho, Luis Claúdio Nascimento da Silva, Julianna Ribeiro Alves dos Santos, Flaviane Maria Galvão Rocha, Cristina de Andrade Monteiro

Abstract


The increase of Candida infections in the last few decades is alarming and the resistance development to antifungals, especially fluconazole, the most widely used drug for treatment, enhances the importance of these infections. Thus, identifying new substances and provide the pharmaceutical industry with the most effective drugs is imperative. Goals were to show the antifungal, anti-biofilm, and synergistic actions between fluconazole (FLZ) and hydroalcoholic extract of Terminalia catappa (TcHE) against Candida vaginal isolates. TcHE was analyzed for anti-Candida activity by agar diffusion and microdilutions assays. Totoxicity was evaluated by the hemolytic test and in larvae of Tenebrio molitor. The effect of TcHE on Candida cells was evaluated by flow cytometry analysis and interference of TcHE on biofilms by MTT assay. In vivo Candida infection and treatment with TcHE was analysed in T. molitor larvae. TcHE showed antifungal activity against all strains tested. The extract was not cytotoxic among concentrations of 3 to 100 mg/mL. Moreover, combinations of TcHE with FLZ have considerably increased the anti-yeast activity (FICI ≤ 0.5). Our findings indicated that TcHE promoted cell membrane instability probably causing plasma membrane damage in C. albicans, resulting in increased cell membrane permeability. These results could also explain the synergistic activity observed between TcHE and fluconazole. TcHE exhibited anti-biofilm properties against C. albicans strains. The antifungal activity and the low cytotoxic potential demonstrated by TcHE reveal that it is promising for development as a new antimycotic

 


Keywords


Terminalia catappa. Antifungals, Candida albicans, Synergism, Plants extracts.

Full Text:

PDF

References


AKHARAIYI, F.C.; ILORI, R.M.; ADESIDA, J.A. Antibacterial effect of Terminalia catappa on some selected pathogenic bacteria. Int. J. Pharm. Biomed. Res, v. 2, p. 64–7. 2011.

ALVES, M. B. et al. Prevalence of Candida spp. from samples of vaginal secretion and its relationship to factors associated with vulvovaginitis Rev. Investig, Bioméd. v. 7, p. 58-68. 2015, doi: https://doi.org/10.24863/rib.v7i1.20

ANAND, A. V.; DIVYA, N.; KOTTI, P. P. An updated review of Terminalia catappa. Pharmacogn Rev, v. 9 (18), p. 93-8. 2015, DOI:10.4103/0973-7847.162103

BORUJENI S. et al. Comparison of vaginal ointment of honey and clotrimazole for treatment of vulvovaginal candidiasis: A random clinical trial, J. Mycol Med, v. 27(4), p. 494-500, 2017, doi: 10.1016/j.mycmed.2017.07.003

CHANDA, S. et al. Antimicrobial, antioxidant, and synergistic properties of two nutraceutical plants: Terminalia catappa L. and Colocasia esculenta L. Turk J Biol. v. 37, p. 81-91, 2013, doi: 10.3906/biy-1203-41

CLINICAL AND LABORATORY STANDARDS INSTITUTE. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard M27-A3, 3rd ed. Clinical and Laboratory Standards Institute, Wayne, PA. 2008.

DA SILVA A. F. et al. Antifungal and Antivirulence Activities of Hydroalcoholic Extract and Fractions of Platonia insignis Leaves against Vaginal Isolates of Candida Species. Pathogens. v. 9(2), p. 84. 2020, doi:10.3390/pathogens9020084biofilme

DA SILVA, A. R. et al. Berberine antifungal activity in fluconazole-resistant pathogenic yeasts: action mechanism evaluated by flow cytometry and biofilm growth inhibition in Candida spp. Antimicrob Agents Chemother, v. 60 (6), p 3551-3557. 2016, doi: 10.1128/AAC.01846-15

DA SILVA, L. C. N. et al. pCramoll and rCramoll as New Preventive Agents against the Oxidative Dysfunction Induced by Hydrogen Peroxide. Oxid Med Cell Longev, v. 2015, p. 520872. 2015, doi: 10.1155/2015/520872.

DE ARAUJO, A. R. et al. Antibacterial, antibiofilm and cytotoxic activities of Terminalia fagifolia Mart. extract and fractions. Ann Clin Microbiol Antimicrob, v. 14, p. 25, 2015, doi: 10.1186/s12941-015-0084-2.

DE OLIVEIRA SANTOS, G.C. et al. Candida infections and therapeutic strategies: mechanisms of action for traditional and alternative agents. Front. Microbiol. v. 9, p. 1351. 2018, doi: 10.3389/fmicb.2018.01351

DORLING, J.; MORAES, C.; ROLFF, J. Recognition, survival and persistence of Staphylococcus aureus in the model host Tenebrio molitor. Dev Comp Immunol, v. 48 (2), p. 284-90. 2015, doi: 10.1016/j.dci.2014.08.010

EL-HOUSSAINI, H. H. et al. Correlation between antifungal resistance and virulence factors in Candida albicans recovered from vaginal specimens. Microb Pathog. v. 128: p. 13‐19. 2019, doi:10.1016/j.micpath.2018.12.028

FERRO, T. A. F. et al. Cinnamaldehyde inhibits Staphylococcus aureus virulence factors and protects against infection in a Galleria mellonella Model. Front. Microbiol. v. 7, p. 2052. 2016, doi: 10.3389/fmicb.2016.02052

FREITAS, A. L. D. et al. Proanthocyanidin polymeric tannins from Stryphnodendron adstringens are effective against Candida spp. isolates and for vaginal candidiasis treatment. J Ethnopharmacol, v. 216, p. 184-190. 2018, doi: 10.1016/j.jep.2018.01.008

HARTMANN, A. et al. Incidência de Candida spp. na mucosa oral de pacientes infectados pelo Vírus da Imunodeficiência Humana (HIV) no município de Santo Ângelo-RS. R Epidemiol Control Infec, v. 6 (3), p. 125-130. 2016, DOI: http://dx.doi.org/10.17058/reci.v6i3.6556

HOLZER, I. et al. The colonization with Candida species is more harmful in the second trimester of pregnancy. Arch Gynecol Obstet, v. 295, p. 891–895. 2017, doi 10.1007/s00404-017-4331-y

JOHNSTON, P. R.; MAKAROVA, O.; ROLFF, J. Inducible defenses stay up late: temporal patterns of immune gene expression in Tenebrio molitor. G3 (Bethesda), v. 4 (6), p. 947-955, 2013, doi: 10.1534/g3.113.008516

KHAN, M. et al. Antifungal susceptibility testing of vulvovaginal. Infect Drug Resist, v. 11, p. 447-456. 2018, doi: 10.2147/IDR.S153116

KLEPSER, M. E. et al. Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B tested against Candida albicans. Antimicrob Agents Chemother, v. 41 (6), p 1392-1395. 1997.

KLIONSKY, D. J. et al. The fungal vacuole: composition, function, and biogenesis. Microbiol Rev, v. 54, p. 266-292, 1990, doi: 10.1128/MMBR.54.3.266-292.1990

LEAL, M. R. D. et al. Treatment of vulvovaginal candidiasis and new therapeutic perspectives: A narrative review. J. Physiother. Res, v. 6(4), p. 462-469. 2016, doi: 10.17267/2238-2704rpf.v6i4.1021

LIMA, J. S. et al. Genotypic analysis of secreted aspartyl proteinases in vaginal Candida albicans isolates. J Bras Patol Med Lab, v. 54 (1), p. 28-33. 2018, doi.org/10.5935/1676-2444.20180006

LIMA, F.R.A. et al. Ethanolic extracts of Momordica charantia L. and Azadirachta indica A. Juss in the physiological and healthy quality of seeds of Moringa oleifera Lam. Braz. J. of Develop., v. 6 (8), p. 60030-60046, 2020, doi:10.34117/bjdv6n8-425

LOCKE, J. B. et al. Time-Kill Kinetics of Rezafungin (CD101) in Vagina-Simulative Medium for Fluconazole-Susceptible and Fluconazole-Resistant Candida albicans and Non-albicans Candida Species. Infect Dis Obstet Gynecol. v. 2018: p. 7040498. 2018, doi:10.1155/2018/7040498

LOCKE, J.B. et al. Time-Kill Kinetics of Rezafungin (CD101) in Vagina-Simulative Medium for Fluconazole-Susceptible and Fluconazole-Resistant Candida albicans and Non-albicans Candida Species. Infect Dis Obstet Gynecol. v. 2018, p. 7040498. 2018, doi:10.1155/2018/7040498

MACHADO-GONÇALVES, L. et al. Effects of Terminalia catappa Linn. Extract on Candida albicans biofilms developed on denture acrylic resin disc. J Clin Exp Dent, v. 10(7), p. e642-7, 2018, doi:10.4317/jced.54776

MARCHAIM, D. et al. Fluconazole-resistant Candida albicans vulvovaginitis. Obstet Gynecol. v. 120(6), p. 1407‐1414. 2012, doi:10.1097/aog.0b013e31827307b2

MEDEIROS, A. P M. et al. Characterization of virulence factors of vaginal and anal isolates of Candida albicans sequentially obtained from patients with vulvovaginal candidiasis in north-east Brazil. J Mycol Med, v. 27 (4), p. 567-572. 2017, doi: 10.1016/j.mycmed.2017.06.002

MESSINA, M. E. JR.; HALABY, R. Does triptolide induce lysosomal-mediated apoptosis in human breast cancer cells? Med. Hypotheses. v. 77, p. 91-93, 2011, doi: 10.1016/j.mehy.2011.03.034

MININEL, F.J. et al. Characterization and quantification of compounds in the hydroalcoholic extract of the leaves from Terminalia catappa Linn. (Combretaceae) and their mutagenic activity. Evid Based Complement Alternat Med, v. 2014: p. 676902, 2014, doi.org/10.1155/2014/676902

MTIBAA, L. et al. Vulvovaginal candidiasis: Etiology, symptomatology and risk factors. J Mycol Med, v. 27 (2), p. 153-158. 2017, doi: 10.1016/j.mycmed.2017.01.003.

NAIR, R.; CHANDA, S. Antimicrobial Activity of Terminalia catappa, Manilkara zapota and Piper betel Leaf Extract. Indian J Pharm Sci, v. 70 (3), p. 390-3. 2008.

NCUBE, B.; FINNIE, J.F.; VAN STADEN, J. In vitro antimicrobial synergism within plant extracts combinations from three South African medicinal bulbs. J. Ethnopharmacol. v. 139: p. 81–89, 2012, doi: 10.1016/j.jep.2011.10.025

NEELAVATHI, P.; VENKATALAKSHMI, P.; BRINDHA, P. Antibacterial activities of aqueous and ethanolic extracts of terminalia catappa leaves and bark against some pathogenic bacteria. Int. J. Pharm. Biomed. Res, v. 5, p. 114-120. 2013.

NGOUANA, T. K. et al. Potent and synergistic extract combinations from Terminalia catappa, Terminalia mantaly and Monodora tenuifolia against pathogenic yeasts. Medicines, v. 2 (3), p. 220-235. 2015, doi: 10.3390/medicines2030220

NOBILE, C. J.; JOHNSON, A. D. Candida albicans biofilms and human disease. Annu Rev Microbiol., v. 69, p. 71–92. 2015, doi:10.1146/annurev-micro-091014-104330.

NWADIOHA, S. I. 1 et al. Risk factors for vaginal candidiasis among women attending primary health care centers of Jos, Nigeria. J. Clin. Med. Res., v. 2(7), p. 110-113. 2010.

ONYEWU, C. et al. Ergosterol biosynthesis inhibitors become fungicidal when combined with calcineurin inhibitors against Candida albicans, Candida glabrata, and Candida krusei. Antimicrob. Agents Chemother. v. 47, p. 956–964. 2003, doi: 10.1128/aac.47.3.956-964.2003

RAUTEMAA R.; RAMAGE G. Oral candidosis--clinical challenges of a biofilm disease. Crit Rev Microbiol. v. 37(4), p. 328‐336. 2011, doi:10.3109/1040841X.2011.585606

SANGLARD, D.; COSTE, A.T. Activity of isavuconazole and other azoles against Candida clinical isolates and yeast model systems with known azole resistance mechanisms. Antimicrobial Agents Chemotherapy, v. 60, p. 229-238. 2016, doi: 10.1128/AAC.02157-15

SANTOS JR, I. D. D. et al. Características gerais da ação, do tratamento e da resistência fúngica ao fluconazol. Scientia Medica, v. 15 (3): p. 89-197. 2005.

SANTOS, J. R. et al. Dynamic interaction between fluconazole and amphotericin B against Cryptococcus gattii. Antimicrob Agents Chemother, v. 56 (5), p. 2553-2558. 2012, doi: 10.1128/AAC.06098-11

SHUKLA, V.; BHATHENA, Z. Sustained release of a purified tannin component of Terminalia chebula from a titanium implant surface prevents biofilm formation by Staphylococcus aureus. Appl. Biochem. Biotechnol,. v. 175, p. 3542-3556, 2015, doi: 10.1007/s12010-015-1525-2

SIIKALA, E. et al. Persistent Candida albicans colonization and molecular mechanisms of azole resistance in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) patients. J Antimicrob Chemother, v. 65, p. 2505–2513. 2010, doi: 10.1093/jac/dkq354

SOBEL, J. D. Vulvovaginal candidosis. Lancet. v. 369 (9577), p. 1961-1971. 2007, doi:10.1016/S0140-6736(07)60917-9.

SOBEL, J.D. Recurrent vulvovaginal candidiasis. Am. J. Obstet. Gynecol. v. 214, p. 15–21. 2016.

SOUZA, P. C. et al. Tenebrio molitor (Coleoptera: Tenebrionidae) as an alternative host to study fungal infections. J Microbiol Methods, v. 118, p. 182-6. 2015, doi: 10.1016/j.mimet.2015.10.004

TAFF, H. T. et al. Mechanisms of Candida biofilm drug resistance. Future Microbiol, v. 8, p. 1325-1327, 2013, DOI:10.2217/fmb.13.101

TAGANNAA, J. C. et al. Tannin-rich fraction from Terminalia catappa inhibits quorum sensing (QS) in Chromobacterium violaceum and the QS-controlled biofilm maturation and LasA staphylolytic activity in Pseudomonas aeruginosa. J Ethnopharmacol., v. 134, p. 865–871, 2011, doi: 10.1016/j.jep.2011.01.028

TERÇAS, A. G. et al. Phytochemical characterization of Terminalia catappa Linn. extracts and their antifungal activities against Candida spp. Front Microbiol, v. 8, p. 595. 2017, doi: 10.3389/fmicb.2017.00595

XU, C. et al. The anthracenedione compound bostrycin induces mitochondria mediated apoptosis in the yeast Saccharomyces cerevisiae. FEMS Yeast Res, v. 10, p. 297–308, 2010, http://dx.doi.org/10.1111/j.1567-1364.2010.00615.x

ZANNI, P. C. M. D. et al. Virulence factors and genetic variability of vaginal Candida albicans isolates from HIV-infected women in the post-highly active antiretroviral era. Rev Inst Med Trop Sao Paulo, v. 59, p. 44-54. 2017, doi: 10.1590/S1678-9946201759044.




DOI: https://doi.org/10.34117/bjdv6n10-358

Refbacks

  • There are currently no refbacks.